Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.02 · Revenue $16.37M · 1 analysts
Est. EPS $0.08 · Revenue $18.13M · 1 analysts
Est. EPS $0.10 · Revenue $65.26M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $59.4M | +4.4% | -16.4% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-1.2M | -125.0% | -161.3% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +48.0% | -4.3% | +8.9% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -1.9% | -122.5% | -303.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -2.0% | -124.0% | -212.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-5.0M | -172.0% | -62.6% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -8.5% | -169.0% | -94.6% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 114.5% | -29.2% | +0.0% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 0.96x | +2.9% | -1.2% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $27.0M | -16.6% | -5.1% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.08 vs 0.12 | -166.7% | -0.05 vs -0.05 | +6.2% |
| Revenue Surprise | $59.4M vs $58.5M | +1.5% | $13.8M vs $12.9M | +7.4% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Nov 5, 2025 | Breitfeld Philip P. | director | Option to purchase Common Stock | A | 13,790 | $6.80 |
| Nov 5, 2025 | SIDRANSKY DAVID | director | Option to purchase Common Stock | A | 21,216 | $6.80 |
| Nov 5, 2025 | Mendelson Daniel Newman | director | Option to purchase Common Stock | A | 13,790 | $6.80 |
| Nov 5, 2025 | TOBIN SCOTT R | director, 10 percent owner: | Option to purchase Common Stock | A | 25,460 | $6.80 |
| Nov 5, 2025 | ACKERMAN JOEL | director | Option to purchase Common Stock | A | 21,216 | $6.80 |
Operator: Good day, everyone, and welcome to the Champions Oncology Fourth Quarter Fiscal Year 2026 Earnings Call. It is now my pleasure to hand the floor over to your host, Robert Brainin, CEO of Champions Oncology. Sir, the floor is yours. Thank you. Robert Brainin: Good afternoon, and thank you for joining our fiscal 2026 year-end earnings call. I'm Rob Brainin, CEO of Champions Oncology, and I'm joined today by our CFO, David Miller. Before we begin, I'll remind everyone that today's remarks may include forward-looking statements. Actual results may differ materially, and you can find more information in our filings with the SEC. I'd like to begin by referring back to what I said shortly after stepping into this role in late August 2025. I said then that we will build on the progress the company has made over recent years, stay focused on positive adjusted EBITDA for the year and at the same time, keep investing in our 2 growth vectors, data and Corellia, with the returns on those investments coming in later quarters and years as well as continuing to invest in our TOS business, especially around growth areas like the radioligand platform. I'm pleased to say our execution against that plan held up well. In fiscal 2026, we delivered record annual revenue and met our commitment to full year positive adjusted EBITDA, including positive adjusted EBITDA in each of the 4 quarters on its own, the first time that has happened since fiscal 2022, driven by real strength in our core services business. Our data business did not repeat its fiscal 2025 revenue, but the comparison is less telling than it looks, and I'll come back to why later in my remarks. And we invested across the organization to build for the next phase of growth. That combination produced a record top line as well as positive adjusted EBITDA alongside a GAAP net loss that reflects those deliberate investments. Our translational oncology services business had its strongest year in the company's history. Services revenue grew to a record $58.7 million, up approximately 12% over the prior year as previously booked studies converted well and our PDX Bank continued to differentiate us in a market where model quality and characterization matter more every year. I want to thank our operations team again who delivered that growth without material additions to headcount, which is the operating leverage we've been describing starting to show up in the numbers. As we said before, quarterly results can vary, primarily due to the timing of study completions. So we evaluate the business on an annual basis. After this year's strong conversion, we'd expect services growth to moderate to a more normalized pace in the near term. The underlying demand environment is healthy, and our focus is on continuing to expand bookings and the future pipeline of work. In terms of data, the year-over-year comparison does not tell the complete story. Data license revenue was approximately $800,000 for fiscal 2026 …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Ronnie Morris | Executive Chair | USD 600,000 | — | 1966 | Active |
David Barry Miller | Chief Financial Officer | USD 308,333 | Male | 1969 | Active |
Robert Brainin | Chief Executive Officer & Director | USD 20,000 | Male | 1972 | Active |
Maria Mancini | Chief Operating Officer | — | — | — | Active |
Marianna Zipeto | Executive Vice President of Growth, Strategy & Enablement | — | — | — | Active |
Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
Champions Oncology NASDAQ: CSBR reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or TOS, services business and efforts to bring radiopharmaceutical work in-house.
Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2026. Fourth Quarter and Other Financial Highlights: Record annual revenue of $59.4 million Fourth quarter revenue of $13.8 million Fourth quarter oncology services margin of 51% Adjusted EBITDA of $158,000 for the quarter and $1.6 million for the fiscal year Adjusted EBITDA income all four quarters in FY 2026 Continued investment in radiopharmaceuticals, the data platform and commercial organization Robert Brainin, CEO of Champions, commented, "Fiscal 2026 marked a year of meaningful progress in executing our strategic priorities as we delivered record annual revenue while continuing to invest in the capabilities we believe will support our next phase of growth.
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
